Oncternal Therapeutics (ONCT) - Financial and Strategic SWOT Analysis Review

October 2019 | 40 pages | ID: O710F13F6A22EN
GlobalData

Abstracts

Oncternal Therapeutics (ONCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oncternal Therapeutics (Oncternal) is a biopharmaceutical company that discovers, develops and commercializes novel targeted hormonal therapies. It develops small molecules that targets hormone pathways for the treatment of various cancers including breast and prostate cancer; and other serious medical conditions. The company has license agreement with the university of tennessee research foundation (UTRF) under which it is developing selective androgen receptor degrader, (SARD) technology. It develops compounds based on SARD technology which can antagonize or degrade multiple forms of androgen receptor and potentially inhibiting the tumor growth in patients resistant to progressive castration prostate cancer or those patients with resistant to current androgen therapies. Oncternal is headquartered in Memphis, Tennessee, the US.

Oncternal Therapeutics Key Recent Developments

Mar 11,2019: GTX investor alert by the former Attorney General Of Louisiana: Kahn Swick & Foti Investigates Merger of GTx - GTXI
Oct 22,2018: GTx reports third quarter 2018 financial results and provides corporate update
Aug 14,2018: GTx provides corporate update and reports second quarter 2018 financial results
May 15,2018: GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results
Mar 12,2018: GTx Reports Fourth Quarter and Full Year 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Oncternal Therapeutics - Key Facts
Oncternal Therapeutics - Key Employees
Oncternal Therapeutics - Key Employee Biographies
Oncternal Therapeutics - Major Products and Services
Oncternal Therapeutics - History
Oncternal Therapeutics - Company Statement
Oncternal Therapeutics - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
Oncternal Therapeutics - Business Description
Oncternal Therapeutics - SWOT Analysis
SWOT Analysis - Overview
Oncternal Therapeutics - Strengths
Oncternal Therapeutics - Weaknesses
Oncternal Therapeutics - Opportunities
Oncternal Therapeutics - Threats
Oncternal Therapeutics - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Oncternal Therapeutics, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 11, 2019: GTX investor alert by the former Attorney General Of Louisiana: Kahn Swick & Foti Investigates Merger of GTx - GTXI
Oct 22, 2018: GTx reports third quarter 2018 financial results and provides corporate update
Aug 14, 2018: GTx provides corporate update and reports second quarter 2018 financial results
May 15, 2018: GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results
Mar 12, 2018: GTx Reports Fourth Quarter and Full Year 2017 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Oncternal Therapeutics, Key Facts
Oncternal Therapeutics, Key Employees
Oncternal Therapeutics, Key Employee Biographies
Oncternal Therapeutics, Major Products and Services
Oncternal Therapeutics, History
Oncternal Therapeutics, Key Competitors
Oncternal Therapeutics, Ratios based on current share price
Oncternal Therapeutics, Annual Ratios
Oncternal Therapeutics, Interim Ratios
Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Oncternal Therapeutics, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Oncternal Therapeutics, Performance Chart (2014 - 2018)
Oncternal Therapeutics, Ratio Charts
Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

GlaxoSmithKline Plc
Gilead Sciences Inc
CellCentric Ltd
Astellas Pharma Inc
Cogentix Medical Inc
Zenith Epigenetics Ltd
Pfizer Inc
Johnson & Johnson
Incyte Corp
Carmot Therapeutics Inc